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By the end of October 2020, the severe acute respi-ratory syndrome coronavirus 2 (SARS-CoV-2) 
pandemic had spread to 6 continents and caused 
>45 million coronavirus disease (COVID-19) cases 
and 1.1 million deaths (1). Despite having 15.6% of 
the worldwide population (2), by October 31, 2020, 
Africa had only 3.9% (1.76 million) of the world’s 
COVID-19 cases and 3.6% (42,233) of deaths during 
the pandemic (1). Data suggest that the pandemic 
is evolving differently in sub-Saharan Africa com-
pared with the rest of the world and that the out-
break started later (3).
Of note, severe COVID-19 cases seem to occur 
less frequently in Africa than in the rest of the world 
(4). Several factors have been proposed to explain 
this. Age is likely a major factor because older per-
sons are at higher risk for severe disease, but Africa 
has an extremely young population; >60% of persons 
are <25 years of age (5). However, variation of CO-
VID-19 severity with age alone does not fully explain 
the observed differences (4). Clinical cases and deaths 
in Africa likely are underreported because systematic 
surveillance is limited and no systematic death regis-
tration exists; thus, the true SARS-CoV-2 burden prob-
ably is underestimated (4). Nevertheless, local health 
systems in Africa, which have a lower capacity to deal 
with COVID-19 patients than healthcare systems in 
high-resource settings, were not overwhelmed, even 
at the peak of the epidemic (6). Although potential 
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ing	 115	deaths;	 67%	of	 cases	were	 identifi	ed	 in	August.	
Among	infections,	MRCG	staff		accounted	for	191	cases;	all	
were	asymptomatic	or	mild.	The	cumulative	incidence	rate	
among	 nonclinical	MRCG	 staff		 was	 124	 infections/1,000	
persons,	which	is	>80-fold	higher	than	estimates	of	diag-




avoidance of medical care during the pandemic, as 
described in other regions (7), could partly explain 
the low number of hospitalized patients, the milder 
COVID-19 disease severity reported appears to be 
genuine, and several biologic and environmental fac-
tors have been proposed as potential contributing 
factors (8–10).
Recent serosurveys conducted in Kenya, Malawi, 
and South Africa showed that community transmis-
sion was several times higher than that detected by 
surveillance; 5%–40% of the population had SARS-
CoV-2 IgG (11–13). Such results highlight the need for 
robust epidemiologic studies to assess the extent of 
community transmission in different regions in Africa.
The Gambia is the smallest country in continen-
tal mainland Africa and is surrounded by Senegal, 
except for its narrow Atlantic coast. Although an im-
ported case was identified in The Gambia on March 
17, 2020, by June 30, 2020, only 48 additional cases had 
been detected. Nevertheless, a rapid increase in cases 
was seen in July 2020, and by the end of September 
2020, 3,579 cases were reported (1). The trajectory of 
the epidemic in The Gambia is different from that in 
Senegal, which has a population ≈7 times larger than 
The Gambia. In Senegal, community transmission 
was reported in early April 2020, and almost 7,000 
cases were recorded by the end of June (1). Systemat-
ic surveillance, testing, contact tracing for staff of the 
Medical Research Council Unit The Gambia (MRCG) 
at the London School of Hygiene and Tropical Medi-
cine (https://www.mrc.gm) who had influenza-like 
symptoms was implemented during the pandemic; 
the first case among MCRG staff was identified on 
July 18. We considered MRCG staff as a cohort to 
provide additional insights into the nature of the CO-
VID-19 epidemic in The Gambia.
Methods
Population Demographics, Climate, and  
Healthcare Structure
In 2020, The Gambia had a population of ≈2.42 mil-
lion. The median age is 17.8 years, and ≈41.9% of 
the population are 20–64 years of age. About 95% of 
the population is Muslim. The illiteracy rate is high 
across the country. Around 59% of the population 
live in urban and peri-urban settings, mainly along 
the coast (Figure 1). 
The climate is typical of the sub-Sahel region, 
including a long dry season during November–May 
and a short rainy season during June–October. Maxi-
mum temperature is high throughout the year, 30°C–
34°C, and lowest during the rainy season; minimum 
temperatures range from 22°C–24°C during the rainy 
season to 16°C−20°C during the dry season  (14). Hu-
midity can be >80% during the rainy months (15).
The government of The Gambia is the main 
health provider, and healthcare delivery has 3 tiers, 
based on the primary healthcare strategy in which 
most healthcare delivery occurs at local health posts. 
The Gambia has 4 tertiary hospitals, 38 health centers 
at the secondary level, and 492 health posts at the pri-
mary level. The system is complemented by 34 pri-
vate and nongovernmental organization clinics.
COVID-19 Response in The Gambia
Shortly after the first COVID-19 case was detected in 
The Gambia on March 19, 2020, the country closed its 
international land, sea, and air borders. On March 27, 
the country declared a state of emergency, which in-
cluded closing schools, nonessential shops, places of 
worship, and many workplaces. Initial SARS-CoV-2 
testing by PCR was focused on identifying imported 
cases and tracing and isolating case contacts, espe-
cially among travelers from Senegal. The Ministry of 
Health, supported by several international organiza-
tions, set up a hotline for the public, which persons, 
including those with suspected cases, could call to 
ask for advice or request the surveillance team to per-
form the SARS-CoV-2 test either at health facilities or 
at home. 
As the epidemic progressed, the Ministry of Health 
established testing facilities at strategic locations in the 
most densely populated parts of the country, mainly 
the western urban areas. Persons were encouraged to 
go for testing if they were symptomatic or after contact 
with a confirmed COVID-19 case. Demand for testing 
services was not high, and attempts to raise awareness 
were unsuccessful. All identified cases were isolated 
in designated facilities regardless of symptoms until 
considered noninfectious as per World Health Organi-
zation (WHO) guidelines (16). Ministry of Health staff 
traced and quarantined contacts for 10 days in hotels 
during the early part of the outbreak, April–July 2020, 
after which persons were permitted to self-isolate for 
10 days at home.
MRCG Unit 
MRCG is a biomedical research institution that 
also provides outpatient and inpatient clinical care 
to the local population through its clinical servic-
es department (CSD). As of August 2020, MRCG 
had 1,336 employees. Staff were distributed as fol-
lows: 845 were along the coast, mainly in Fajara; 
158 were in Keneba; 116 were in the Central River 




Upper River Division, mainly Basse (Figure 1). 
MRCG staff work in different environments, includ-
ing 715 (53.5%) field-based staff, such as drivers, 
community workers, nurses, and research clinicians; 
334 (25.0%) office-based staff, including those in ad-
ministrative, operations, data-management, and sta-
tistics positions; and 177 (13.2%) laboratory-based 
staff. Only 110 (8.2%) MRCG staff provide health-
care to the general population at the CSD.
CSD is 1 of 2 hospital facilities in The Gambia able 
to care for severe COVID-19 patients. CSD dedicat-
ed 42 beds for COVID-19 patients, including MRCG 
staff and the general population. From the start of the 
epidemic, all staff were trained to wear appropriate 
personal protective equipment (PPE) according to in-
ternational guidelines (17).
MRCG staff underwent a clinician-administered 
risk assessment in the early phases of the epidemic. 
Staff deemed to be at high risk for severe disease were 
advised to work from home and were excluded from 
high-risk clinical areas.
Surveillance and Contact Tracing among MRCG Staff
In July 2020, MRCG established enhanced passive 
case detection by testing all staff exhibiting COV-
ID-19 symptoms, such as cough, fever, headache, sore 
throat, nasal congestion, body pain, or other influen-
za-like symptoms. Families and contacts of symp-
tomatic staff also were tested, as were staff known to 
have been exposed to confirmed cases. In addition, 
CSD staff were offered active weekly PCR-based test-
ing, regardless of symptoms. MRCG set up a hotline 
manned by doctors from whom staff could receive 
answers to questions or concerns and get information 
on how to access services. Case contacts were called 
to confirm exposure and then tested 3–5 days after the 
last exposure. Regardless of negative test results, all 
exposed staff were quarantined for 14 days; SARS-
CoV-2–positive staff isolated in their homes for 14 
days, or at the MRCG site if at-home isolation was not 
possible, in line with WHO recommendations (18). 
Sample Collection
Samples were collected via nasopharyngeal swab, 
oropharyngeal swab, or both by using FLOQSwabs 
(COPAN Diagnostics, https://www.copanusa.com). 
Samples were placed in single tubes containing uni-
versal transport medium (COPAN Diagnostics) and 
delivered to the laboratory within 24 hours. Sampling 
methods were comparable across cohorts with simi-
lar operational procedures and training.
Laboratory Methods for SARS-CoV-2 Detection
MRCG laboratories collaborated with national 
public health laboratories to support national test-
ing throughout the country during the epidemic. 
MRCG and these laboratories used the same labora-
tory methods and assays. Because the outbreak was 
expected to spread to the West Africa subregion, 
MRCG staff attended an Africa Centres for Disease 
Control and Prevention (https://africacdc.org) re-
gional training workshop on diagnosing COVID-19, 
which was held in February 2020 in Dakar, Senegal. 
Thereafter, The Gambia established laboratory pro-
tocols for processing and testing suspected SARS-
CoV-2–infected samples according to WHO guide-
lines (19,20). The same procedures and assays were 
transferred to the laboratory.
The standard test for COVID-19 diagnosis in The 
Gambia is real-time reverse transcription PCR (RT-
PCR) of SARS-CoV-2–specific viral gene sequences. In 
the early stages of the outbreak, RT-PCR diagnosis was 
made by using the Berlin Charité Laboratory protocol 
(21), which targets the RNA-dependent RNA poly-
merase and envelope protein gene. Subsequent tests 
kits, primarily the Da An Gene Nucleic Acid Extraction 
Kit (Da An Gene Co., Ltd., of Sun Yat-sen University, 





(2019-nCoV) Nucleic Acid Diagnostic Kit (Sansure Bio-
tech, Inc., http://eng.sansure.com.cn) were donated to 
the national public health libraries; both tests target 
the open reading frame 1ab and the nucleocapsid gene 
coding regions.
Sample inactivation and downstream RNA ex-
traction were done by using commercially available 
kits according to the manufacturers’ protocols. Ini-
tial extractions were performed manually by using 
the QIAamp Viral RNA Mini Kit (QIAGEN, https://
www.qiagen.com) or the IndiSpin Pathogen Kit (IN-
DICAL BIOSCIENCE, https://www.indical.com). 
When donations to the public health system became 
available, kits from the Da An Gene Co., Ltd., of Sun 
Yat-sen University and Sansure Biotech, Inc., were 
included. As the outbreak progressed and daily 
sample numbers increased, automated RNA extrac-
tion system on the QIAcube HT (QIAGEN) was im-
plemented. In all cases, 200 µL of universal transport 
medium sample was processed, and the RNA eluted 
in 50–80 µL, depending on the extraction kit. RT-
PCR analysis was conducted with 5 µL of extracted 
RNA in 25 µL of reaction mix containing reaction 
buffer, one-step reverse transcription enzyme, ei-
ther the Takara One Step PrimeScript III RT-PCR Kit 
(TaKaRa Bio, Inc., http://www.takara-bio.com) or 
SuperScript III Platinum One-Step qRT-PCR Kit (In-
vitrogen, https://www.thermofisher.com), and the 
primer and probe mix. 
Samples were defined as positive if amplification 
of any viral gene occurred after 40 cycles and with all 
the controls amplifying as appropriate. We defined a 
COVID-19 case as any person with a SARS-CoV-2–
positive RT-PCR from a nasopharyngeal or oropha-
ryngeal swab sample, regardless of symptomatology.
Statistical Analysis
We calculated rates of risk for COVID-19 per 1,000 
persons among the population of The Gambia. For 
MRCG, we stratified rates by occupational clinical 
exposure for staff working at the CSD versus non-
CSD staff. In addition to occupational clinical expo-
sure, surveillance for CSD staff was more intense 
due to routine testing, regardless of symptoms or 
known exposure.
The Ministry of Health generated daily national 
data for The Gambia (22). We extracted compiled data 
from the publicly available Johns Hopkins University 
COVID-19 database (23). The Gambian Government/
MRCG Joint Ethics committee approved the study 
(reference no. L2020.E37).
Results
Persons <25 years of age and persons >60 years of 
age are underrepresented in the MRCG cohort com-
pared with the population of The Gambia, (Table). 
In addition, urban residents are overrepresented 
in the MRCG cohort; 67.6% of MRCG staff live 
in cities or towns compared with 59.4% of the over-
all population.
SARS-CoV-2 Positivity Rates
From the start of the epidemic through September 
30, 2020, a total of 17,885 samples were tested in 
The Gambia; 20.1% (3,590) were SARS-CoV-2–posi-
tive. The positivity rate was lower before July (1.6%; 
40/3,095 samples tested) and higher during July–Sep-
tember (23.7%; 3,499/14,790 samples tested) (19,20). 
The number of samples collected and the positivity 
rate were the highest during August–September 2020, 
during which time the number of daily swabs collect-
ed varied from 28 to 524/day (median 184/day) (Fig-
ure 2). Positivity rate also varied substantially, from 
<5% to >50%. Approximately 67% of confirmed cases 
were detected in August; overall, 60% of confirmed 
cases were among persons <40 years of age (20).
During July 1–September 30, a total of 937 sam-
ples were collected from the MRCG cohort; 191 
 
Table. Epidemiologic	and	demographic	characteristics	of	the	population	of	The	Gambia	and	staff	of	MRCG* 
Baseline	characteristics The	Gambia,	no.	(%) MRCG	staff,	no.	(%) 
Age groups, y†   
 <25 1,549,084	(64.2) 51	(3.89) 
 25–34 367,334	(15.2) 450	(34.35) 
 35–44 217,500	(9.0) 381	(29.08) 
 45–54 132,917	(5.5) 307	(23.44) 
 55–64 72,500	(3.0) 113	(8.63) 
 >65 74,917	(3.1) 8	(0.61) 
Median	age,	y 17.8 37.5 
Sex   
 M 1,193,834	(49.4) 915	(68.5) 
 F 1,220,418	(50.6) 421	(31.5) 
Living in main towns or cities‡ 1,420,600	(59.4) 903	(67.6) 
*MRCG,	Medical	Research	Council	Unit	The	Gambia	at	the	London	School	of	Hygiene	and	Tropical	Medicine. 
†Ages were missing for 6 MRCG staff. 




(20.4%) were SARS-CoV-2–positive. Most (60%) con-
firmed cases were detected in August. The median 
age among MRCG staff with SARS-CoV-2–positive 
samples was 36 years.
Rates of Infection and Death
By the end of September 2020, the cumulative rate 
of infection among the population of The Gambia 
≈1.5/1,000 persons (Figure 3, panel A). During the 
same period, 115 COVID-19 deaths were recorded 
across the country.
Among MRCG staff, stratified analysis showed 
that infection rates among CSD staff were 2.6 times 
higher than among non-CSD staff, whom we consid-
ered representative of the infection risk among the 
general population (Figure 3, panel B). By the end of 
September, the cumulative risk for infection among 
non-CSD MRCG staff was ≈124/1,000 persons (Fig-
ure 3, panel B). All 191 confirmed cases among 
MRCG staff were either asymptomatic or mildly 
symptomatic; no cases met WHO criteria for moder-
ate or severe pneumonia and no deaths occurred in 
this cohort.
Discussion
The COVID-19 pandemic arrived in The Gambia in 
July 2020, later than in most countries in the world. 
The Gambia had a short and intense first wave; 67% 
of cases occurred in August, and most cases were as-
ymptomatic or mild. Among our MRCG cohort, 1/7 
(14.3%) persons were SARS-CoV-2–positive. During 
the epidemic peak, the SARS-CoV-2 positivity rate 
among the population of The Gambia was >20%.
The later start of the epidemic is probably the re-
sult of the early closure of national borders, including 
for air travel, and of the identification and isolation of 
infected persons who continued to enter the country 
from Senegal. These measures were complemented 
by contact tracing and by the provision of facilities 
for quarantine by the government. The relative ef-
fects of these measures, together with other measures 
implemented during the state of emergency, such as 
closure of schools, reduction of access to markets, 
banning of large gatherings including at religious fes-
tivals, and use of facemasks, are hard to quantify, as 
are behavioral changes, such as social distancing and 
handwashing. Nonetheless, these measures seem to 
have been key in preparing the country to respond 
and minimize potential harm. 
The sudden increase of cases in August coincided 
with the major Muslim feast of Eid-Ul Adha, locally 
called Tobaski, on July 30, 2020, during which travel 
and family gatherings were common. However, the 
number of COVID-19 cases had already started to in-
crease in July. 
Although climate in The Gambia is hot through-
out the year, the peak epidemic coincided with the 
months of highest daily humidity and highest mini-
mum temperature but lowest maximum temperature 
(14,15). Data on how temperature and humidity affect 
transmission are contradictory (24,25). In The Gambia, 
climate conditions might have had an indirect effect on 
transmission because persons are more likely to spend 
time indoors during the rainy season. In The Gambia, 
the rainy season also occurs during the months with 












Through the systematic testing of the MRCG staff 
cohort, including asymptomatic contacts and mildly 
symptomatic cases, we might have more robust esti-
mates of the actual rates of SARS-CoV-2 infection in 
The Gambia than are available from the general popu-
lation. The rate of SARS-CoV-2 in MRCG staff outside 
the CSD (124 cases/1,000 persons) was >80-fold higher 
than that reported for the general population. Rates 
among MRCG staff remained >40-fold higher than the 
general population, even when we considered only the 
more intensely populated coastal area of The Gambia in 
the denominator. Assuming the urban adult population 
had similar exposures and transmission as our MRCG 
cohort, we would expect >75,000 infections among the 
601,394 persons 20–64 years of age who live in main 
towns. This estimation contrasts sharply with the 
3,579 cases reported during the same period across 
the country and in all age groups, a discrepancy that 
could be partly explained by the high occurrence 
of asymptomatic or mildly symptomatic infections 
and the national testing strategy that used passive 
case detection and targeted symptomatic persons. 
Because >50% of the population is <20 years of age, 


































infections in The Gambia. Indeed, the discrepancies be-
tween estimated and reported cases we noted are con-
sistent with recent seroprevalence studies from eastern 
and southern Africa. Those studies suggest higher rates 
of community infection compared with those estimat-
ed by passive case surveillance. For instance, 3 weeks 
after the COVID-19 peak in South Africa, 40% of HIV-
positive pregnant women had SARS-CoV-2 antibodies 
(12). In Kenya, a retrospective survey of blood donor 
samples collected during April–June 2020 found that 1 
in 20 adults had SARS-CoV-2 antibodies (13). In Mala-
wi, SARS-CoV-2 seroprevalence was 12.3% in a cohort 
of 500 healthcare workers sampled during May–June 
2020; using the observed seroprevalence, the research-
ers concluded that the predicted number of deaths was 
8 times the number of reported deaths (11). In a smaller 
study of 113 frontline healthcare workers in Nigeria, 
45% had SARS-CoV-2 antibodies (27). In The Gambia, 
>30% of the CSD staff became infected by September 
30, 2020. Rates among CSD staff were higher than the 
rest of the MRCG cohort, which probably reflects a 
combination of stronger surveillance and occupational 
clinical exposure exacerbated by traveling to work, but 
the weight of each factor is difficult to estimate. How-
ever, higher seroprevalence has been reported among 
healthcare workers in Europe (28).
The prevalence of mild disease also is reflected 
by the low occupancy of hospital beds reserved for 
severe COVID-19 patients. However, the fewer hos-
pitalizations also could indicate avoidance of SARS-
CoV-2 testing because of stigmatization, which has 
been observed in other regions (7). Indeed, among 
the 115 COVID-19 deaths counted in The Gambia, 
30% of SARS-CoV-2 tests were performed postmor-
tem on samples collected from patients hospitalized 
in non–COVID-19 health facilities. Without an official 
registration system for deaths, the overall toll of CO-
VID-19–associated deaths is difficult to quantify, and 
the real number could be several times higher.
The low occurrence of severe disease in Africa 
compared with other continents underlines the im-
portance of minimizing the potential collateral dam-
age of the COVID-19 pandemic. Such damage in-
cludes diversion of financial and personnel resources 
from other services to the COVID-19 response, chang-
es in healthcare seeking behavior, reduced availabil-
ity of medicines for acute and chronic diseases, and 
disruption of routine vaccination services (29–33). 
The pandemic also has worsened the economic sta-
bility of households and increased food insecurity, 
particularly in low- and middle-income countries 
(34), and mitigating the short- and mid-term effects of 
the pandemic should be a priority. Use of COVID-19 
restriction measures to control transmission must be 
carefully weighed against the economic effects these 
measures have on the population. Tackling fear and 
stigma will be essential to avoid decreases in health 
system use in future COVID-19 waves.
One limitation of our study is that, although cas-
es in the general population and the MRCG cohort 
showed similar timelines and the size of the MRCG 
cohort is relatively large, MRCG cases could be con-
sidered a cluster. In addition, the level of education 
and the monthly income of MRCG staff is above that 
of the general population, thus, staff likely understand 
and are able to better implement prevention mea-
sures. MRCG staff live mainly in urban areas, where 
transmission tends to be higher (35), but they also live 
in less crowded environments with better access to 
water and sanitation, which could protect them from 
infection. MRCG also developed policies, launched 
many levels of staff education on COVID-19, and re-
inforced messages related to social distancing, hand-
washing, and the wearing of face masks at work and 
in the community. Given the nature of the MRCG’s 
work, the level of understanding and background 
knowledge of infectious diseases, even among staff 
not directly involved in research, likely is higher than 
for the general population. The rapid identification 
and isolation of cases through the robust surveillance 
among MRCG staff should have further limited trans-
mission. On the other hand, no moderate or severe 
COVID-19 cases occurred among the MRCG staff. 
The mild clinical manifestations among cases were 
not modified by treatment; for instance, no MRCG 
staff member met WHO criteria for hospitalization 
and fewer required oxygen supplementation or dexa-
methasone treatment. The prevalence of risk factors 
for severity should be similar between MRCG staff 
and the population, except the MCRG cohort had 
fewer persons >60 years of age, which is a primary 
risk factor for severe COVID-19 and death. 
In conclusion, SARS-CoV-2 transmission in The 
Gambia was intense over a short period. Reassuring-
ly, COVID-19 seems less severe in The Gambia than 
in high-income countries in Europe, North America, 
and Asia. It is unclear whether a second wave of in-
fection will occur because the causes of the sudden 
increase of cases in July are unclear. We strongly en-
courage continuous protection of healthcare workers 
with appropriate PPE and strengthening of surveil-
lance systems around the country to promptly de-
tect another sudden increase of cases. Countrywide 
seroprevalence surveys would clarify the epidemiol-
ogy of infection in different age groups and places. 
However, engaging with the community to mitigate 
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collateral damage of the pandemic should take prior-
ity. In addition, investigation is needed to define the 
major drivers that shape the epidemic so differently 
in Africa than in some high-income regions. Clarify-
ing such drivers should help model adequate inter-
ventions for both low- and high-income countries.
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